Figure 4 | British Journal of Cancer

Figure 4

From: Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma

Figure 4

Representative composite images (scale bar: 500 μm) of PaCa13 tumours showing EF5 (red), CD31 (blue), and nuclear (grey) staining after treatment with vehicle control (0.9% saline), maximum tolerated dose gemcitabine (MTD gem; 240 mg kg−1 on days 1, 8, and 15), or metronomic gemcitabine (30 mg kg−1, q3d) for 4 weeks. Squares, magnified images (scale bar: 83 μm) of the corresponding areas in the tumour sections.

Back to article page